NCT03207958View on ClinicalTrials.gov

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

June 4, 2022

Study Completion Date

February 9, 2024

Conditions

Graft Vs Host DiseaseGraft-versus-host-disease

Interventions

DRUG

Belimumab

-Given over 1 hour

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

American Cancer Society, Inc.

OTHER

lead

Washington University School of Medicine

OTHER

NCT03207958 - Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter